Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Active, not recruiting Phase 1Phase 2 Interventional Results available

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

NCT03534323
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions
Duvelisib, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Miami, Florida • Brewer, Maine • Boston, Massachusetts + 1 more
Conditions
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
Interventions
CC-486 (5-azacitidine), Duvelisib, Romidepsin, Doxorubicin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL)
Interventions
Duvelisib, Ibrutinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Tempe, Arizona • Hot Springs, Arkansas • La Jolla, California + 5 more
Conditions
Peripheral T-cell Lymphoma
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Conditions
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Duvelisib, Nivolumab, Positron Emission Tomography, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more
Conditions
Mycosis Fungoides, Cutaneous T-cell Lymphoma
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hepatic Impairment
Interventions
IPI-145
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
IPI-145, Ofatumumab
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
14
States / cities
La Jolla, California • Denver, Colorado • Fort Myers, Florida + 9 more
Conditions
T-Cell Lymphoma
Interventions
Duvelisib, Peripheral blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Hematologic Malignancy
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Conditions
Unresectable Melanoma
Interventions
Nivolumab, Duvelisib
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Indolent Non-Hodgkin Lymphoma
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Fort Myers, Florida • Lecanto, Florida • Orange City, Florida + 3 more
Conditions
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
Interventions
BMS-986345, Duvelisib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
Interventions
IPI-145, Rituximab, Bendamustine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Oklahoma City, Oklahoma + 1 more
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Duvelisib, Tisagenlecleucel
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Conditions
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions
Ruxolitinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Conditions
Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Duvelisib, Positron Emission Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California